Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)‘s stock had its “neutral” rating reiterated by analysts at Citigroup Inc. in a report released on Tuesday. They currently have a $150.00 price objective on the biopharmaceutical company’s stock. Citigroup Inc.’s price target indicates a potential upside of 143.55% from the company’s current price.

A number of other equities research analysts have also recently issued reports on the stock. Cowen and Company reaffirmed an “outperform” rating and issued a $232.00 target price on shares of Intercept Pharmaceuticals in a report on Thursday, September 14th. Wells Fargo & Company reaffirmed an “outperform” rating on shares of Intercept Pharmaceuticals in a report on Wednesday, September 13th. Jefferies Group LLC initiated coverage on shares of Intercept Pharmaceuticals in a report on Monday, July 10th. They issued a “buy” rating and a $275.00 target price on the stock. Cantor Fitzgerald reaffirmed an “underweight” rating and issued a $69.00 target price on shares of Intercept Pharmaceuticals in a report on Wednesday, September 13th. Finally, Zacks Investment Research raised shares of Intercept Pharmaceuticals from a “hold” rating to a “buy” rating and set a $136.00 target price on the stock in a report on Tuesday, July 11th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $174.37.

Intercept Pharmaceuticals (NASDAQ:ICPT) traded down 16.43% during trading on Tuesday, reaching $61.59. The company’s stock had a trading volume of 11,858,999 shares. Intercept Pharmaceuticals has a 52 week low of $60.97 and a 52 week high of $172.95. The company’s 50 day moving average price is $106.75 and its 200 day moving average price is $115.74. The company’s market cap is $1.55 billion.

Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its quarterly earnings data on Monday, July 31st. The biopharmaceutical company reported ($3.46) EPS for the quarter, topping the Zacks’ consensus estimate of ($3.62) by $0.16. Intercept Pharmaceuticals had a negative net margin of 543.35% and a negative return on equity of 135.24%. The company had revenue of $30.89 million during the quarter, compared to the consensus estimate of $27.50 million. During the same period in the prior year, the business posted ($3.14) EPS. The company’s quarterly revenue was up 459.6% on a year-over-year basis. On average, equities analysts anticipate that Intercept Pharmaceuticals will post ($13.91) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This article was first posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this article on another website, it was illegally stolen and reposted in violation of United States and international copyright and trademark law. The correct version of this article can be accessed at https://theolympiareport.com/2017/09/19/citigroup-inc-reaffirms-buy-rating-for-intercept-pharmaceuticals-inc-icpt.html.

In related news, insider Lisa Bright sold 253 shares of the stock in a transaction that occurred on Friday, August 25th. The shares were sold at an average price of $111.31, for a total transaction of $28,161.43. Following the sale, the insider now owns 23,324 shares in the company, valued at approximately $2,596,194.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Mark Pruzanski sold 40,000 shares of the stock in a transaction that occurred on Monday, June 26th. The stock was sold at an average price of $130.80, for a total transaction of $5,232,000.00. Following the sale, the chief executive officer now owns 611,718 shares in the company, valued at approximately $80,012,714.40. The disclosure for this sale can be found here. Insiders have sold 48,013 shares of company stock worth $6,198,747 over the last ninety days. Insiders own 9.20% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. FMR LLC boosted its position in shares of Intercept Pharmaceuticals by 0.7% during the 2nd quarter. FMR LLC now owns 3,750,678 shares of the biopharmaceutical company’s stock worth $454,094,000 after acquiring an additional 25,958 shares in the last quarter. Carmignac Gestion boosted its position in shares of Intercept Pharmaceuticals by 0.4% during the 2nd quarter. Carmignac Gestion now owns 2,035,592 shares of the biopharmaceutical company’s stock worth $246,449,000 after acquiring an additional 7,400 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Intercept Pharmaceuticals by 4.5% during the 2nd quarter. Vanguard Group Inc. now owns 1,328,133 shares of the biopharmaceutical company’s stock worth $160,797,000 after acquiring an additional 57,149 shares in the last quarter. State Street Corp boosted its position in shares of Intercept Pharmaceuticals by 7.3% during the 1st quarter. State Street Corp now owns 805,550 shares of the biopharmaceutical company’s stock worth $91,110,000 after acquiring an additional 54,523 shares in the last quarter. Finally, First Trust Advisors LP boosted its position in shares of Intercept Pharmaceuticals by 17.0% during the 2nd quarter. First Trust Advisors LP now owns 287,411 shares of the biopharmaceutical company’s stock worth $34,797,000 after acquiring an additional 41,856 shares in the last quarter. Institutional investors and hedge funds own 82.19% of the company’s stock.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.